NASDAQ:AKUS

Akouos - AKUS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: $13.29
▼
$13.29
50-Day Range: $13.29
▼
$13.29
52-Week Range: $2.32
▼
$13.60

Volume: 440 shs
Average Volume: 344,411 shs
Market Capitalization: $490.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.50

Institutional Ownership

About Akouos (NASDAQ:AKUS) Stock

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Receive AKUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter.

AKUS Stock News Headlines

December 1, 2022 | finance.yahoo.com

Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases

November 14, 2022 | finance.yahoo.com

Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights

March 27, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

October 19, 2022 | seekingalpha.com

Akouos stock soars 87% as Lilly nabs hearing loss gene therapy developer - Seeking Alpha

October 18, 2022 | businesswire.com

AKUS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akouos, Inc. Is Fair to Shareholders - Business Wire

October 18, 2022 | benzinga.com

Crude Oil Drops Over 2%; Akouos Shares Spike Higher - Akouos (NASDAQ:AKUS), ADS-TEC Energy (NASDAQ:ADSE) - Benzinga

October 18, 2022 | nasdaq.com

Eli Lilly to buy genetic medicine developer Akouos for $487 million - Nasdaq

October 18, 2022 | marketwatch.com

Eli Lilly to Buy Akouos for Up to $610 Million >LLY AKUS - MarketWatch

March 27, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

October 18, 2022 | marketwatch.com

Akouos Shares Soar on Takeover by Eli Lilly >AKUS - MarketWatch

October 18, 2022 | marketwatch.com

Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss - MarketWatch

October 18, 2022 | nasdaq.com

Eli Lilly To Buy Akouos For Up To $610 Mln - Nasdaq

October 18, 2022 | streetinsider.com

Eli Lilly & Co. (LLY) Acquires Akouos (AKUS) for $610M - StreetInsider.com

October 10, 2022 | nasdaq.com

Akouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why - Nasdaq

October 10, 2022 | finance.yahoo.com

Akouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why

September 29, 2022 | seekingalpha.com

AKUS stock rated Bullish at William Blair on gene therapy for hearing loss (NASDAQ:AKUS) - Seeking Alpha

September 27, 2022 | finance.yahoo.com

Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures - Yahoo Finance

September 14, 2022 | uk.investing.com

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday By Benzinga - Investing.com UK

September 14, 2022 | finance.yahoo.com

Alcohol Justice to Participate at Alcohol Policy-19 Evidence to Action: Building a Framework for Change - Yahoo Finance

September 13, 2022 | finance.yahoo.com

FDA Clears Akouos' Gene Therapy Trial For Genetic Form Of Hearing Loss

September 13, 2022 | finance.yahoo.com

Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss

September 13, 2022 | markets.businessinsider.com

Akouos Says FDA Clears IND Application For AK-OTOF For OTOF-mediated Hearing Loss

September 13, 2022 | seekingalpha.com

Akouos stock rises 11% on FDA clearance to start gene therapy trial for hearing loss - Seeking Alpha

September 9, 2022 | streetinsider.com

Form SC 13G/A Akouos, Inc. Filed by: FEDERATED HERMES, INC. - StreetInsider.com

August 18, 2022 | nasdaq.com

Akouos, Inc. (AKUS) Upgraded to Buy: Here's Why - Nasdaq

August 18, 2022 | finance.yahoo.com

Akouos, Inc. (AKUS) Upgraded to Buy: Here's Why

August 16, 2022 | benzinga.com

This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday - Benzinga

See More Headlines

Receive AKUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter.

AKUS Company Calendar

Last Earnings: 11/12/2021
Today: 3/26/2023
Next Earnings (Estimated): 4/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AKUS
CUSIP: N/A
CIK: 1722271
Web: www.akouos.com
Phone: 857-410-1818
Fax: N/A
Employees: 103
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.50
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: -5.9%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.62)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-86,670,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -45.09%
Return on Assets: -36.86%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.30
Quick Ratio: 17.30

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.90 per share
Price / Book: 2.71

Miscellaneous

Outstanding Shares: 36,936,000
Free Float: 35,163,000
Market Cap: $490.88 million
Optionable: Not Optionable
Beta: -0.55

Key Executives

Dr. Emmanuel Simons M.B.A. (Age 39)
Ph.D., Co- Founder, Pres, CEO & Director
Comp: $790.72k

Dr. Michael John McKenna M.D. (Age 65)
Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board
Comp: $539.35k

Ms. Jennifer Anne Wellman M.S. (Age 44)
Chief Operating Officer
Comp: $568.67k

Dr. Luk H. Vandenberghe M.D.
Ph.D., Founder & Member of Scientific Advisory Board

Mr. William F. Sewell Ph.D.
Founder & Member of Scientific Advisory Board

Mr. Richard Smith M.D.
Founder & Member of Scientific Advisory Board

Ms. Sachiyo Minegishi (Age 44)
CFO, Treasurer, Assistant Sec. & Principal Accounting Officer

Ms. Stacy Price
Chief Technical Officer

Dr. Aaron Tward M.D.
Ph.D., Chief Scientific Officer

Dr. Karoline K. Shair
Sr. VP, Gen. Counsel, Chief Legal Officer & Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AKUS Stock - Frequently Asked Questions

Should I buy or sell Akouos stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akouos in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AKUS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKUS, but not buy additional shares or sell existing shares.
View AKUS analyst ratings or view top-rated stocks.
What is Akouos' stock price forecast for 2023?: 3 brokers have issued 12-month target prices for Akouos' stock. Their AKUS share price forecasts range from $12.00 to $13.00. On average, they anticipate the company's share price to reach $12.50 in the next year. This suggests that the stock has a possible downside of 5.9%.
View analysts price targets for AKUS or view top-rated stocks among Wall Street analysts.
When is Akouos' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our AKUS earnings forecast.
How were Akouos' earnings last quarter?: Akouos, Inc. (NASDAQ:AKUS) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.04.
What other stocks do shareholders of Akouos own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akouos investors own include NVIDIA (NVDA), Honeywell International (HON), QUALCOMM (QCOM), Raytheon Technologies (RTX), CVS Health (CVS), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Home Depot (HD), Pfizer (PFE) and Procter & Gamble (PG).
When did Akouos IPO?: (AKUS) raised $124 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager.

What is Akouos' stock symbol?: Akouos trades on the NASDAQ under the ticker symbol "AKUS."
Who are Akouos' major shareholders?: Akouos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Credit Suisse AG (0.04%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
What is Akouos' stock price today?: One share of AKUS stock can currently be purchased for approximately $13.29.
How much money does Akouos make?: Akouos (NASDAQ:AKUS) has a market capitalization of $490.88 million. The company earns $-86,670,000.00 in net income (profit) each year or ($2.62) on an earnings per share basis.
How many employees does Akouos have?: The company employs 103 workers across the globe.
How can I contact Akouos?: Akouos' mailing address is 645 SUMMER STREET SUITE 200, BOSTON MA, 02210. The official website for the company is www.akouos.com. The company can be reached via phone at 857-410-1818 or via email at turiano@sternir.com.

This page (NASDAQ:AKUS) was last updated on 3/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Akouos - AKUS Stock Forecast, Price & News

About Akouos (NASDAQ:AKUS) Stock

AKUS Stock News Headlines

AKUS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AKUS Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info